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The extracellular microenvironment is an integral component of
normal and diseased tissues that is poorly understood owing to its
complexity. To investigate the contribution of the microenvironment
to lung fibrosis and adenocarcinoma progression, two pathologies
characterized by excessive stromal expansion, we used mouse models
to characterize the extracellular matrix (ECM) composition of normal
lung, fibrotic lung, lung tumors, and metastases. Using quantitative
proteomics, we identified and assayed the abundance of 113 ECM
proteins, which revealed robust ECM protein signatures unique to
fibrosis, primary tumors, or metastases. These analyses indicated
significantly increased abundance of several S100 proteins, including
Fibronectin and Tenascin-C (Tnc), in primary lung tumors and associ-
ated lymph node metastases compared with normal tissue. We
further showed that Tnc expression is repressed by the transcrip-
tion factor Nkx2-1, a well-established suppressor of metastatic progres-
sion. We found that increasing the levels of Tnc, via CRISPR-mediated
transcriptional activation of the endogenous gene, enhanced the
metastatic dissemination of lung adenocarcinoma cells. Interroga-
tion of human cancer gene expression data revealed that high TNC
expression correlates with worse prognosis for lung adenocarci-
noma, and that a three-gene expression signature comprising TNC,
S100A10, and S100A11 is a robust predictor of patient survival
independent of age, sex, smoking history, and mutational load.
Our findings suggest that the poorly understood ECM composition
of the fibrotic and tumor microenvironment is an underexplored
source of diagnostic markers and potential therapeutic targets for
cancer patients.
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Tumor progression is a function of the combined effects of ge-netic and epigenetic changes in cancer cells, as well as the in-
fluence of the tumor microenvironment. Both cellular and
noncellular stromal components in the tumor microenvironment
have been shown to affect growth of the primary tumor, progres-
sion to metastasis, and response to various anticancer agents (1).
Characterization of the tumor-associated stroma in many dif-
ferent cancer types has revealed an extensive array of cell types and
structural components that directly affect tumorigenesis (1). In
particular, the noncellular component of the tumor microenvi-
ronment, the extracellular matrix (ECM), has emerged as an im-
portant regulator of cancer development (2). The ECM is a
complex network of secreted macromolecules that surrounds most
cells within tissues and contributes to the establishment and
maintenance of tissue architecture (3). Along with providing the
structural foundation for tissue function and mechanical integrity,
the ECM has various other roles that make it relevant to the pa-
thology of cancer. The ECM serves as a substrate for cell attach-
ment and guides the migration of cells along its fibers. Moreover,
the ECM affects proliferation by acting as a reservoir for growth
factors and chemokines, and regulates the presentation of these
molecules to their corresponding receptors (3). Thus, it is not
surprising that the ECM plays a critical role during tumor cell in-
vasion and metastasis (4, 5). In fact, different adhesive character-
istics of the ECM have been suggested to control key steps of the
metastatic process, including tumor cell intravasation, extravasa-
tion, and metastatic colonization (2).
Although the ECM is a major component of the tumor micro-
environment, our understanding of the changes in ECM compo-
sition during cancer progression remains incomplete, largely due to
technical challenges in comprehensively assaying the ECM in a
sensitive and unbiased manner. In this study, we focused on ana-
lyzing the ECM changes associated with lung cancer, the most
prevalent and deadly cancer type worldwide. Non–small-cell lung
cancers account for 83% of all lung cancers, with lung adenocar-
cinomas the most common subtype. Lung cancer accounts for
more deaths than any other cancer in both men and women (6).
Several clinical studies have noted that increased expression of
certain ECM components, such as versican and hyaluronic acid,
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correlate with higher tumor recurrence rates and more advanced
disease (7), yet their contributions to disease progression or utility
as biomarkers remain unknown.
Because the complexity of the tumor microenvironment cannot
be faithfully recapitulated in cell culture, genetically engineered
mouse models of cancer are well suited to answer questions about
the role of ECM components in tumor development and progres-
sion. In this study, we investigated the role of the ECM in the un-
derlying biology of lung adenocarcinoma in the context of an
autochthonous mouse model that recapitulates the in vivo com-
plexity of cancer initiation and progression. This model is based on
infection of a subset of adult lung epithelial cells with viral
vectors expressing Cre recombinase in mice harboring a LoxP-Stop-
LoxP KrasG12D knock-in allele (KrasLSL-G12D) (8). Cre-mediated
recombination of the transcriptional/translational “stop” element
leads to activation of oncogenic Kras expression under control of its
endogenous promoter, initiating the development of lung adenomas
(8). Concomitant deletion of Trp53 in KrasLSL-G12D/+;Trp53Flox/Flox
(KP) mice significantly promotes tumor progression to malignancy,
leading to the development of lung adenocarcinomas that closely
recapitulate the pathophysiologic features of the human disease. In
the present study, we implemented a label-based, quantitative mass
spectrometry (MS) approach to elucidate the compositional changes
in the ECM accompanying lung cancer progression by profiling the
matrisome of normal lung, primary lung tumors, and lung tumor
metastases to the lymph nodes. The matrisome is defined as the
ensemble of core ECM proteins (e.g., collagens, proteoglycans) and
ECM-associated proteins, which include ECM-affiliated proteins
(e.g., annexins, lectins), ECM regulators (proteases, their inhibitors,
and cross-linking enzymes) and secreted factors (e.g., chemokines,
growth factors, S100 proteins) (9).
To compare ECM changes in lung cancer with other patholog-
ical conditions, we examined the changes associated with pulmo-
nary fibrosis, a common and devastating condition characterized by
the excessive and disordered deposition of ECM that destroys the
normal alveolar structures and thus impairs lung function (10).
There is an urgent need to better understand this condition, be-
cause idiopathic pulmonary fibrosis (IPF) is a fatal disease with a
prognosis worse than the majority of cancers (11). Between
30,000 and 40,000 new cases of IPF are diagnosed each year in the
United States, and the median survival is only 2.5–3.5 y (11). There
are a number of similarities in the biology of IPF and lung cancer,
including common alterations in signal transduction pathways, as
well as in the underlying genetic and epigenetic changes (11).
Moreover, increased abundance of ECM deposition is a key feature
of both diseases, and chronic fibrosis may confer increased risk of
later tumor development (11). Therefore, we reasoned that com-
paring the ECM changes between these conditions would provide
insight into this disease. To this end, we used a mouse model of
pulmonary fibrosis, based on bleomycin administration (12).
This study provides a comprehensive analysis of the matrisome
in in vivo mouse models of fibrosis and metastatic lung cancer.
Our work identifies common and unique components of fibrosis
and lung cancer, and distinguishes changes in the ECM compo-
sition attributable to fibrosis vs. those related to tumorigenesis.
We reveal enrichment of previously uncharacterized proteins in
advanced tumors and provide evidence for the functional in-
volvement of the ECM component Tenascin-C (Tnc) in driving
tumor progression and metastasis. Importantly, we further dem-
onstrate that expression of TNC together with two other matrisome
factors, S100A10 and S100A11, holds prognostic information for
lung adenocarcinoma patients.
Results
Quantitative Proteomic Profiling of the ECM of Normal and Diseased
Lung Tissues. To study the ECM changes associated with lung can-
cer, we isolated normal, healthy lung tissues from wild-type (WT)
mice and microdissected primary lung tumors (hereinafter referred
to as KP tumors) and associated metastases to the mediastinal
lymph node (Fig. 1A). We analyzed only advanced primary tumors
(grades 3 and 4) as confirmed by a pathologist (R. Bronson). To
compare the ECM changes associated with tumor development and
those associated with fibrosis and inflammation, we further isolated
whole lungs from mice treated with bleomycin, a commonly used
animal model of pulmonary fibrosis (12).
Masson’s trichrome staining of paraffin-embedded tissues revealed
that fibrotic lungs, advanced primary tumors, and metastases have
a dramatic accumulation of collagen, the most abundant ECM
component, compared with normal lungs (Fig. 1A). To systemati-
cally characterize the matrisome of normal lung, fibrotic lung,
primary lung adenocarcinoma, and associated lymph node metas-
tases, we used a recently developed proteomics-based approach (9,
13). The four sample types—normal lungs, fibrotic lungs, primary
tumors, and metastatic tumors—were first subjected to a decellu-
larization procedure to remove the soluble intracellular proteins
and to enrich for ECM proteins (Fig. 1B). The quality of the ECM-
enriched fraction was then verified by conducting MS analysis of
each of the 12 prepared samples (Dataset S1). To evaluate the
relative abundance of each ECM protein across the different
sample types, we introduced label-based quantification to our
proteomics pipeline (14). Each peptide sample was labeled with a
unique isobaric tandem mass tag (TMT) (Dataset S2A) before MS
analysis, which allowed us to obtain precise quantitative in-
formation from the samples. Because only 10 TMT tags exist at
present, and because the MS analysis revealed similar ECM
composition in the three normal lung samples (Dataset S1), we
subsequently pooled these control samples and used this pool as a
reference for quantitation in later analyses.
Because the mass spectrometer was operated in a data-
independent manner, we performed two technical replicates (rep-
licates 1 and 2); the overlap between the two replicates was 63%,
which is satisfactory for this type of analysis (Fig. S1 A and B). In
both replicates, >40% of the ∼35,000 identified spectra belonged to
ECM proteins, and resulted in the detection of 25 collagens and
75 additional ECM and ECM-associated proteins (Fig. 1C). To
decrease the frequency of selecting collagen peptides and other
abundant peptides for fragmentation, and thus increase the likeli-
hood of selecting previously unidentified peptides, we constructed
an exclusion list and performed two additional technical replicates
(replicates 3 and 4; Fig. S1 A and B). This analysis revealed an
additional 590 unique peptides (Fig. S1A), 124 of which corre-
sponded to known ECM proteins (Fig. S1B). Although we observed
a 22% decrease in the number of spectra that were on the exclusion
list, it is worth noting that the number of additional unique peptides
identified was similar to that identified in a technical replicate
performed without using the exclusion list. The union of all four
replicates allowed us to quantify the level of detection of 113
ECM and ECM-associated proteins in all 10 samples (Figs. 1D
and 2 and Dataset S2). Annotation of these results using existing
in silico murine matrisome data (9, 15) revealed the presence of
79 core matrisome proteins (43 ECM glycoproteins, 30 collagens,
and 6 proteoglycans) and 34 ECM-associated proteins (14 ECM-
affiliated proteins, 14 ECM regulators, and 6 secreted factors)
(Fig. 2 and Dataset S2C). Pairwise comparisons of the level of
detection of the 113 ECM proteins across all three biological
replicates within each tissue type revealed significant intersample
reproducibility (Fig. S2A).
Independent Component Analysis Identifies ECM Signatures of Fibrotic
Lung, Primary Lung Tumor, and Metastasis.Unsupervised independent
component analysis (ICA) identified three statistically significant
ECM signatures within the dataset, which differentiated between
the three disease states: fibrosis, primary tumor, and metastasis
(Fig. 3A). This approach allowed us to identify the ECM proteins
that were specific to each state (Fig. 3B). We observed increases in
fibronectin (Fn) and the fibrinogen γ and β chains, but a decrease
in osteoglycin, in fibrotic tumors compared with lung tumors.
Similar changes were consistent among independent samples from
different animals, suggesting that these are changes that reflect
consistent alterations of likely functional relevance. Primary lung
tumors and lymph node metastases were characterized by de-
creased levels of nephronectin and fibrinogens, but only primary
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lung tumors contained increased laminin and elastin. Finally, the
metastatic samples showed significant and specific elevations in the
expression of S100A6, S100A11, Tnc, and annexin A2 and de-
creased expression of nidogen and laminin gamma 1. Collectively,
these data demonstrate that unique changes in the ECM compo-
sition can be used to differentiate between different disease states
of the lung.
We used volcano plots to highlight ECM proteins that were
detected in significantly altered abundance in pairwise comparisons
of diseased and normal lungs (Fig. 3C and Dataset S3). Tnc was
present in very low amounts in normal lungs, but was markedly
increased levels in fibrotic and tumor samples (Figs. 2 and 3C).
Fibronectin 1 (Fn), a binding partner of Tnc, was also significantly
more abundant in the disease samples. In addition, three members
of the S100 family of proteins—S100A6, S100A10, and S100A11—
were detected in greater abundance in advanced KP tumors
(approximately fourfold) and metastases (7.5- to 11-fold) com-
pared with normal lung, but were not enriched in fibrotic lung
(Fig. 2). Interestingly, a comparison of the matrisomes of primary
lung tumors and fibrotic lungs revealed only few proteins detected
in significantly different proportions, suggesting that most changes
in the abundance of ECM proteins in tumor samples are similar to
and of the same magnitude as those occurring during fibrosis (Fig.
S2B). Similarly, a comparison of the matrisomes of primary lung
tumors and metastases to lymph nodes identified only the α1 chain
of collagen 3 as expressed in significantly higher amounts in me-
tastases and fibrotic lungs (Fig. S2C). Moreover, analysis of the
overlap between the ECM and ECM-associated proteins identi-
fied in significantly altered abundance in all three conditions
revealed three proteins: Fn, Tnc, and S100A11 (Fig. 2D). There
were also 13 proteins with similar changes between KP tumors and
metastases, and 8 between fibrosis and tumors (Fig. 2D and
Dataset S3F). In summary, analysis of the MS data revealed
common and unique changes in specific ECM components that
characterize the three disease states.
Validation of MS Data by Immunohistochemistry. To confirm the MS
data, we performed immunohistochemistry (IHC) for a subset of
the identified ECM proteins to determine whether their expres-
sion was altered in fibrotic lungs, tumors, and metastases com-
pared with normal lungs. Analysis of S100 protein expression
patterns in normal lungs showed that these proteins were largely
absent from the extracellular space. In the fibrotic lung samples,
the overall expression for the three S100 proteins was relatively
low, which is consistent with the MS analysis (Fig. 3C). In contrast,
primary tumors had a marked increase of all three proteins in the
tumor cells and in the extracellular spaces (Fig. 4 and Fig. S3).
Some tumors were uniformly positive for the S100 factors,
whereas others exhibited patchy expression (Fig. S3), but higher-
grade tumors and aggressive areas were overall positive. Similarly,
S100A6, S100A10, and S100A11 were more abundant in KP lung
metastases to the mediastinal lymph nodes (Fig. 4, Right), whereas
A
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Fig. 1. Enrichment of ECM from lung tissues and
tumors and quantitative proteomic analysis of ECM-
enriched samples. (A) Masson’s trichrome staining of
sections of normal murine lung, fibrotic lung, lung
tumor, and lung tumor metastasis to the lymph node
shows increased deposition of collagen (blue) in dis-
eased lung samples compared with normal lung.
(B) The sequential removal of intracellular components
(steps 1–4) and resulting ECM protein enrichment were
monitored in each sample (normal lung, fibrotic lung,
primary lung tumor, and lung metastasis) by immuno-
blotting for collagen I and Fn (ECM markers), actin
(cytoskeletal marker), GAPDH (cytosolic marker), and
histones (nuclear marker). The insoluble fraction
remaining after serial extraction (highlighted in
blue) was enriched for ECM proteins and largely
depleted for intracellular components. (C) Pie charts
represent the relative distribution of ECM and non-
ECM components in terms of number of spectra
(Left), number of peptides (Middle), and proteins
(Right) identified in the TMT mix composed of pep-
tides from all 12 samples in two technical replicates.
(D) Pie charts represent the relative distribution of
ECM and non-ECM components in terms of number
of spectra (Left), number of peptides (Middle), and
proteins (Right) identified in the TMT mix composed
of peptides from all 12 samples after integrating
data from two additional technical replicates con-
ducted after implementing a spectral exclusion list
(Materials and Methods).
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there was no or very little detectable expression in the normal
lymph nodes. These data support the results of our MS analysis,
and raise the possibility that these proteins can serve as bio-
markers of disease development.
We next examined the expression of Fn, an ECM glycoprotein
commonly bound to integrins, which are known proproliferation
factors (16). IHC analysis revealed that compared with normal
lungs, Fn levels were increased in fibrotic lungs as well as in lung
tumors and their associated metastases (Fig. 4). In the normal
lung, Fn staining was less pronounced, with some expression found
closely associated with blood vessels. In the fibrotic samples, Fn
expression was significantly increased and in a stromal pattern.
The tumor and metastatic samples also showed increased staining
that was associated primarily with the stroma and showed distinct
fibrillar networks (Fig. 4 and Fig. S3).
Finally, we examined the expression of Tnc, an ECM protein that
is highly expressed in the developing embryo but absent in most
adult tissues. Numerous studies have shown reexpression of Tnc at
sites of wound healing or inflammation, as well as in malignant
tumors of diverse origins (17). In agreement with those reports and
with our MS data, there was minimal Tnc staining in the normal
lung, but Tnc expression was dramatically increased at sites of fi-
brosis as well as in tumors and metastases (Fig. 4 and Fig. S3).
In summary, the unique changes identified in each condition
suggest that these ECM proteins might have specific roles in me-
diating the phenotypes associated with the disease state with which
they are associated. Furthermore, the differential staining patterns
raise the possibility that ECM proteins can serve as faithful bio-
markers for each of these disease states.
Regulation of Tnc During Lung Cancer Progression. We focused our
efforts on investigating the ECM protein Tnc, because its IHC
pattern suggested that it may have a role in driving the pathology of
lung fibrosis, as well as during tumor progression and the devel-
opment of metastases. A functional role for Tnc in mice with
bleomycin-induced fibrosis has already been demonstrated; Carey
et al. (18) showed that Tnc-knockout animals are protected against
fibrosis and exhibit significantly lower accumulation of collagen in
the lungs. Thus, we chose to focus on the role of Tnc in lung ad-
enocarcinomas using the KP model.
To dissect some of the molecular details of the regulatory net-
works that are affected during cancer progression and lead to up-
regulation of expression of Tnc, we used a collection of cell lines
isolated from KP mice that are representative of different stages of
tumor progression. Tnonmet cells were isolated from nonmetastatic
primary KP tumors, whereas Tmet and Met cell lines were harvested
from metastatic primary tumors and their metastases to the lymph
nodes or liver, respectively (19). Analysis of existing gene expression
array data from these cell lines identified that, among other changes,
Tnc was significantly up-regulated in Tmet and Met cells, but not in
the nonmetastatic Tnonmet lines (P = 0.0001) (19). To confirm this
observation, we isolated mRNA from these cell lines and performed
quantitative RT-PCR (qPCR) analysis for Tnc expression. Although
there was almost no Tnc expression in cell lines isolated from lower-
grade Tnonmet cells, Tnc transcript levels were markedly up-regulated
in both the Tmet and Met lines (Fig. 5A). These observations suggest
a possible role for Tnc in tumor progression to metastasis.
The transcription factor Nkx2-1 has been shown to inhibit
tumor progression by repressing genes involved in metastasis
(19). Given our observed anticorrelation between the patterns of
expression of Nkx2-1 and Tnc in the cell lines (Fig. 5A), we hy-
pothesized that Tnc also might be subject to Nkx2-1 repression. To
examine this possibility, we analyzed Nkx2-1 chromatin immuno-
precipitation sequencing (ChIP-seq) data (20) that identified
Nkx2-1 binding sites in Kras-driven lung tumors, and discovered
that Nkx2-1 binds the murine Tnc locus at four distinct regions
Fig. 2. List of 113 quantified ECM proteins in normal
and diseased lung samples. For each protein, the av-
erage log2 TMT ratio was calculated for the following
comparisons: fibrotic lung samples/normal lung sam-
ple, fibrotic lung samples/lung tumor samples, lung
tumor samples/normal lung sample, and lymph node
metastasis samples/lung tumor samples. The proteins
are divided into categories constituting the matri-
some: ECM glycoproteins (Left), collagens and pro-
teoglycans (Middle), and ECM-associated proteins
including ECM regulators, ECM-affiliated proteins,
and ECM-associated secreted factors (Right).
E5628 | www.pnas.org/cgi/doi/10.1073/pnas.1707054114 Gocheva et al.
near the transcription start site (Fig. 5B). We confirmed these data
by ChIP and quantitative PCR (ChIP-qPCR) with primers specific
to the four putative binding regions in the Tnc locus, and observed
that Nkx2-1 bound to these regions with a strength comparable to
that of a canonical Nkx2-1 target gene, SftpA (Fig. 5C). These
results suggest that Nkx2-1 represses Tnc in KP tumor cells.
To determine whether Nkx2-1 is necessary and sufficient to
control Tnc expression, we performed loss-of-function and com-
plementary gain-of-function experiments. We observed that shRNA-
mediated silencing of Nkx2-1 in two different Tnonmet cell lines
indeed led to the derepression of Tnc (Fig. 5D). Analysis of pre-
viously published gene expression data on Tnonmet cell lines
expressing shRNA for Nkx2-1 showed that Tnc levels increase fol-
lowing Nkx2-1 knockdown in three independent Tnonmet cell lines
(19). Conversely, Tnc levels were strongly down-regulated in a TMet
cell line following exogenous expression of Nkx2-1 cDNA (Fig. 5D).
Consistent with a repressive effect of Nxk2-1 on Tnc, we observed
a strong anticorrelation expression pattern in KP tumors in vivo. We
stained and analyzed more than 100 KP primary tumors and con-
sistently observed that regions lacking Nkx2-1 expression were Tnc-
positive (Tncpos) (Fig. 5E and Fig. S4). Both high-grade tumors and
high-grade areas within otherwise lower-grade tumors that were
Nkx2-1–negative (Nkx2-1neg) were strongly Tncpos (Fig. 5E). In
contrast, early-stage tumors that expressed high levels of Nkx2-1 were
uniformly Tnc-negative (Tncneg). Importantly, we did not observe
any Nkx2-1pos/Tncpos and Nkx2-1neg/Tncneg tumors. Staining of serial
sections of high-grade KP tumors for Tnc and smooth muscle actin
revealed that despite the widespread presence of fibroblasts in
these high-grade tumors, the presence of Tnc was restricted to the
Nkx2-1neg areas (Fig. S5). We conclude that the progressive loss of
Nkx2-1 during lung adenocarcinoma progression is responsible for
the derepression of Tnc observed in late-stage tumors.
Tnc Enhances theMetastatic Potential of Lung Tumor Cells.To determine
whether up-regulation of Tnc is causal to the more aggressive and
metastatic phenotype observed in late-stage tumors, we used the
synergistic activation mediator (SAM) CRISPR/Cas9 system to in-
duce Tnc expression in tumor cells (21). This three-component
system comprises a catalytically inactive dCas9 fused to the tran-
scriptional activator VP64 and a modified guide RNA (gRNA)
scaffold containing twoMS2 RNA aptamers, which recruit the MS2-
P65-HSF1 tripartite synthetic transcriptional activator (21). It is
important to note that the SAM system offers an unprecedented
approach to gain-of-function studies, because Tnc is >7.5 kb long,
making exogenous expression of this gene using traditional over-
expression viral constructs challenging. To transcriptionally activate
Tnc from its endogenous locus, we designed and cloned five in-
dependent gRNA sequences specific to the Tnc promoter. Expres-
sion of Tnc-specific gRNAs in KP cells expressing the SAM
components resulted in 5- to 500-fold activation of Tnc expression
as assessed by qPCR (Fig. 6A). We chose the two gRNAs (gTNC5
and 6) that induced the greatest Tnc expression, and validated Tnc
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Fig. 3. ECM signatures distinguish fibrotic, primary
tumor, and metastatic states. (A) Analysis of proteomic
data reveals three distinct statistically significant sig-
natures (P < 0.01) characterizing fibrosis, primary lung
tumor, and metastatic samples. Although each signa-
ture in the row-normalized heatmap is characterized
by low protein levels (blue), each signature is two-
sided, allowing for identification of proteins with
high levels that characterize each of the states. Blue
indicates lower protein levels compared with yellow
(higher levels). (B) Heat maps for each of the three
signatures show representation of enriched or de-
pleted proteins (jzj > 1.75). Rows represent standard-
ized median-centered values for a given protein,
where blue indicates relatively lower levels than red.
(C) Volcano plots illustrate pairwise differential ex-
pression changes (using log2 median-centered values)
between each of fibrotic, lung tumor, and metastatic
samples compared with the normal lung. Each dot
represents a protein. The x axis indicates a log2-fold
change over the normal sample (positive values rep-
resent up-regulation compared with the normal sam-
ple). The y axis is −log10 of the two-sided t test P value
indicating the significance of differential gene expres-
sion compared with the normal sample. The horizontal
red dashed line represents the P < 0.05 significance
threshold. The vertical dashed red lines represent up
and down fold change thresholds of 1.5× . Blue dots
represent significant differentially expressed genes (P <
0.05 and FC > 1.5×). Several proteins of interest (all
significant) are highlighted in red; a complete list is
provided in Dataset S3. (D) Venn diagram represents
the overlap between ECM and ECM-associated pro-
teins found in significantly altered abundance in lung
fibrosis, lung tumor, and metastasis. The three proteins
found in significantly different abundance in all three
conditions are Fn, Tnc, and S100A11 (a complete list is
provided in Dataset S3F).
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protein induction by immunofluorescence (Fig. 6B) and Western
blot analysis (Fig. S6A). Although Tnc expression was mostly in-
tracellular shortly after cell seeding (Fig. 6B), over time the majority
became secreted (Fig. S6A). Overexpression of Tnc did not affect
the proliferation rate of cells in culture (Fig. S6B).
We next used the Tnc-overexpressing cell lines to test whether
increased Tnc levels could promote tumor progression in a mouse
model of metastasis that assays for the ability of cells to disseminate
to distant organs (Fig. 6C). Whereas Tnc overexpression had no
effect on primary tumor growth after subcutaneous transplantation
(Fig. 6D), it had a significant effect on promoting the metastatic
colonization of the lungs (Fig. 6E). Increased tumor burden in the
lungs was observed with both Tnc-specific gRNAs (5- to 35-fold
increase), and all inoculated animals developed metastases. TNC
staining in the primary tumors and lung metastases was fibrillar (Fig.
S6 C and D).
To further investigate the role of Tnc during the metastatic
process, we performed tail vein metastasis assays, which test for the
ability of tumor cells to extravasate, colonize, and grow in secondary
sites (Fig. 6F). Tnc overexpression led to high levels of the protein
as shown by IHC (Fig. 6G and Fig. S7), along with a significant
increase in metastasis to the lungs (Fig. 6H). This set of experiments
establish a direct role for Tnc in promoting metastasis in lung ad-
enocarcinoma and provide further evidence that the overexpression
of Tnc observed in advanced and metastatic tumor cells play an
important role in the aggressive phenotype of these tumors.
Gene Expression of Specific Matrisome Factors Is Associated with Poor
Prognosis for Lung Adenocarcinoma Patients.We next addressed how
the findings from the mouse models relate to human lung cancer.
We first investigated whether similar changes in the expression
levels of TNC, as well as the other four factors identified and
validated through our analysis, were found in patients with lung
adenocarcinoma. To this end, we analyzed RNA-seq gene ex-
pression profiles of primary tumors, matched normal samples, and
relevant clinical data obtained from The Cancer Genome Atlas
(TCGA) lung adenocarcinoma (LUAD) cohort. TNC levels were
significantly higher in tumors compared with normal lungs across
the entire dataset as well as in matched tumors compared with
normal tissue from the same patient (Fig. 7A and Fig. S8A).
Similarly, expression of S100A6 and S100A11, two other factors
found to be increased in the KP mouse model, was also signifi-
cantly higher (Fig. 7A and Fig. S8A). In contrast, expression of
S100A10 was significantly lower in matched tumor samples com-
pared with normal lungs. FN1 expression was lower across the
entire dataset, although matched tissues from the same patient
exhibited a significant up-regulation (Fig. S8A).
We next explored whether the increased levels of any of these
factors carries prognostic information. Kaplan–Meier 5-y survival
analyses revealed a significantly poorer prognosis in patients with
high TNC expression (top 25%) compared with those with low TNC
expression (Fig. 7B). Similarly, high expression of S100A10 and
S100A11 were correlated with significantly poorer patient prognosis,
whereas high expression of S100A6 or FN1 did not (Fig. 7B and Fig.
S8C). We next investigated whether a combined metric based on
the expression values of the three genes, for which high expression is
correlated with poorer prognosis, would have prognostic value.
We used the geometric mean of the expression values of TNC,
S100A10, and S100A11 (three-gene signature) to score and rank
patients. Higher signature scores were indeed significantly associated
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Fig. 5. Nkx2-1 represses Tnc expression. (A) qRT-PCR analysis of Tnonmet (n = 3),
Tmet (n = 4), and Met (n = 6) cell lines for Tnc (Left) and Nkx2-1 (Right) ex-
pression relative to GAPDH used as control. *P < 0.05, **P < 0.01, unpaired
t test. (B) Analysis of ChIP-Seq data (20) reveals binding of Nkx2-1 in the Tnc
genomic locus at four distinct areas near the transcription start site. (C) ChIP-
qPCR analysis of the enrichment of Nkx2-1 binding at the Tnc genomic locus.
Data represent mean ± SEM of three independent experiments. Sftpa serves as
a positive control. Negative control mapping to a gene desert region onmurine
chromosome 8 (GD8). The Tnc peak numbers correspond to those in B. **P <
0.01, ***P < 0.001, unpaired t test. (D) Western blots showing that Nkx2-
1 knockdown in two different Tnonmet cell lines allows Tnc expression, while
Nkx2-1 overexpression in Tmet cells represses Tnc. Hsp90 was used as a loading
control. (E) Nkx2-1 and Tnc IHC of KP lung adenocarcinomas shows reciprocal
staining. Quantitation of Nkx2-1 and Tnc expression in early-stage (4–6 wk after
initiation) and late-stage KP tumors (>12 wk after initiation).
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with worse patient outcome (Fig. 7C and Fig. S8D) and exhibited
stronger statistical significance (P = 0.00009) than either of the
Kaplan-Meier analyses based on expression of individual genes
(Fig. 7B and Fig. S8E). Interestingly, there was no association
between the three-gene signature and survival in patients with
colorectal cancer, suggesting potential organ and tumor-specific
differences in ECM composition and function (Fig. S8F).
To further evaluate the prognostic value of the three-gene sig-
nature in predicting patient survival, in the context of other clinical
covariates, we used the Cox proportional hazards model to per-
form univariate and multivariable survival analyses on the TCGA
lung adenocarcinoma patient cohort (Fig. 7D). Univariate analysis
indicated that an increasing three-gene signature score was sig-
nificantly associated with poor patient survival (P = 0.0209).
Multivariable analysis, controlling for other covariates (age, sex,
smoking history, and mutational load), also showed a significant
correlation between the three-gene signature and worse survival
(hazard ratio, 1.30; P = 0.00624). Taken together, our findings
provide important information for the prognosis of patients with
lung adenocarcinoma, and suggest that this TNC expression-based
gene signature could serve as a useful biomarker.
Discussion
Although previous studies have examined the changes in individual
components of the ECM in lung cancer and fibrosis, a compre-
hensive approach to characterizing the composition of the ECM in
these disease states has been lacking. In the present study, we used
quantitative proteomics to characterize the global changes in ECM
protein abundance that occur in fibrosis and during lung cancer
development. This analysis was performed in the context of well-
established mouse models that recapitulate the complexity of the in
situ changes that accompany fibrosis and cancer progression. We
compared the ECM changes that occur during tumorigenesis with
those that occur in a mouse model of pulmonary fibrosis to de-
lineate the similarities and differences between these conditions.
Changes in ECM in Lung Fibrosis. Two recent studies have used pro-
teomics to report changes occurring in bleomycin-induced fibrosis
(22, 23). Along with some overlapping findings, our study of the
insoluble ECM has uncovered and quantified additional proteins.
This can be attributed in part to our use of different proteomics
technologies. Collectively, those studies, together with our study,
provide a more complete understanding of the ECM changes that
occur in this model, and the findings possibly could lead to the
identification of novel antifibrotic agents and strategies.
We identified and validated two ECM proteins, Fn and Tnc, as
highly abundant in fibrosis. These findings are consistent with pre-
vious reports in which both proteins were found to be up-regulated
in mouse and rat models of bleomycin-induced pulmonary fibrosis
(22–24). Schiller et al. (23) showed that Tnc is increased at both the
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Fig. 6. Overexpression of Tnc in lung adenocarcinoma
cells promotes metastasis in vivo. (A) Expression of Tnc
mRNA in 1233 KP cells using the SAM system. (B) Im-
munofluorescence analysis of Tnc in control KP cells
compared with cells overexpressing Tnc. Tnc protein is
shown in red; DAPI (blue) staining highlights the nu-
clei. (C) Experimental schematic: 1233 control or Tnc-
overexpressing KP cells were injected s.c. into the
flanks of WT C57BL/6J mice. (D) At 4 wk after injec-
tions, primary tumors were excised and weighed.
(E) The lung metastatic burden was quantified as the
ratio of the metastases area/ total lung area and the
number below the graph show the number of mice
that developed lung metastases. Each dot represents a
mouse (n = 5 for each group). Data represent mean ±
SEM. *P < 0.05, unpaired t test. (F) Experimental
schematic: 1233 control or Tnc-overexpressing KP cells
were injected via the lateral tail vein into WT C57BL/6J
mice. (G) Representative IHC images of Tnc in the lung
metastases. Positive signals are shown in brown; he-
matoxylin (blue) was used as a counterstain. (H) The
area covered by metastases was quantified and di-
vided over total lung area. Data represent mean ±
SEM. **P < 0.01.
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protein and mRNA levels in the lungs of mice treated with bleo-
mycin, and demonstrated that higher Tnc expression is associated
with stiffer lung tissue, a feature of fibrosis. Furthermore, Tnc not
only is a marker of pulmonary fibrosis, but also has been impli-
cated in the pathogenesis of the disease. Tnc-knockout animals are
protected against bleomycin-induced fibrosis and have lower ac-
cumulation of collagen, reduced fibroblast infiltration, and re-
duced activity of TGF-β in the lungs (18). Importantly, patients
with pulmonary fibrosis show increased levels of Tnc, suggesting
that the role of Tnc in pulmonary fibrosis is not limited to animal
models of the disease (25, 26). Whether Tnc contributes to the
development and severity of the disease in humans, and what fac-
tors cause its up-regulation in that setting, remain open questions.
ECM Changes in Cancer. Through delineating the changes that occur
during pulmonary fibrosis and cancer progression, we have identi-
fied unique protein signatures that independently set apart each
condition. Because changes in the composition of the ECM can
have a regulatory role during cancer development and metastasis
formation, we compared primary tumors and metastases both to
normal lung and to each other. Although many factors were sig-
nificantly altered in the tumorigenic state compared with healthy
tissue, there were few statistically significant differences in ECM
between the primary lesions and their associated lymph node me-
tastases. Thus, the ECM at these local metastases closely resembled
that of the primary tumors.
Interestingly of the 20 proteins that we found in higher abun-
dance in the ECM signature of KP lung tumors (compared with
normal lung), nine (Col12a1, Col14a1, Col18a1, Col8a1, Fbln2,
Fn1, Ltbp2, Nid1, and Tnc) were encoded by genes that are part of
the AngioMatrix signature, an ensemble of matrisome genes whose
up-regulation at the mRNA has been associated with the induction
of angiogenesis in the RIP1-Tag2 mouse model of pancreatic
neuroendocrine cancer (27). Tnc was identified as an important
component of the AngioMatrix in driving the angiogenesis in the
neuroendocrine tumor model; the AngioMatrix also has negative
predictive value in patients with glioma and colorectal carcinoma
(27). The partial overlap between the lung tumor matrisome fac-
tors we have identified and the AngioMatrix raises the possibility of
A
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Fig. 7. Prognostic value of matrisome factors within the LUAD patient cohort. (A) Gene expression values (RNA-seq normalized counts standardized for mean = 0,
SD = 1) for a subset of the validated matrisome factors in matched normal lung tissue and primary lung tumors of patients with lung adenocarcinoma (n = 57). Two-
sided P values (Kolmogorov–Smirnov test) are shown. (B) Kaplan–Meier 5-y survival analysis comparing patients in the top 25th percentile of expression for each
gene (n = 114; red) and those in the bottom 75th percentile (n = 344; blue). Log-rank test P values are shown. (C) Kaplan-Meier 5-y survival analysis in TCGA LUAD
using an expression metric to quantify the combined expression levels of S100A10, S100A11, and TNC (three-gene signature). Specifically, the geometric mean of
the expression levels was used to score and rank patients. Shown are the top 45% scoring patients (n = 206) vs. the rest (n = 252). Log-rank test P value is shown
(median survival, 1,043 d for the high-scoring patient subpopulation and 1,725 d for the remainder of the cohort). (D) Results of univariate and multivariable Cox
proportional hazards model on overall survival in the LUAD cohort (all patients). Increasing three-gene signature score shows a significant association with poorer
survival after controlling for other characteristics.
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an angiogenic component to our ECM signature in lung tumors,
which warrants further investigation.
Role of S100 Proteins in Lung Adenocarcinoma. In our present analysis,
three members of the S100 protein family—S100A6, S100A10, and
S100A11—were detected in significantly higher abundance in the
ECM of primary lung tumors and associated metastases.
S100 proteins are regulated by binding of calcium ions, which al-
lows them to act as calcium sensors and thus translate fluctuations
in intracellular calcium levels into the appropriate cellular re-
sponses (28). The S100 proteins can act as extracellular factors as
well. This family of proteins comprises 21 members, each with
distinct functional properties. Although their precise roles are not
well understood, multiple S100 family members exhibit deregu-
lated expression in various cancer types.
Our analysis of patient data revealed that some of the S100 factors
that we have identified in this study are highly expressed in lung
adenocarcinoma tissue, and that this higher expression is correlated
with poor patient prognosis. Several other studies have reported
similar observations, supporting the idea that our findings may be
clinically relevant (29–31). S100A10 expression has been significantly
correlated with higher TNM stage, more frequent vascular invasion,
and a poorer overall prognosis (30). Similarly, in a study of S100A11
expression in 179 tumor samples from patients with lung adeno-
carcinoma, Woo et al. (31) found significantly higher S100A11 levels
in adenocarcinomas with KRAS mutations, as well as in poorly dif-
ferentiated tumors. Moreover, strong S100A11 expression was cor-
related with shorter disease-free survival. Those results suggest that
this protein might be involved in the tumorigenic process specifically
in KRAS-mutant lung adenocarcinomas, the subset of human tumors
that the KP model is designed to represent. Previous work using
RNAi to knock down S100A11 has established that this factor
promotes proliferation of human lung adenocarcinoma cell lines in
vitro and s.c. growth in vivo using xenografts (32). Moreover, several
studies also have suggested that this protein contributes to metastasis
and invasion, and in fact up-regulation of S100A11 in patients with
non–small-cell lung cancer is significantly associated with the pres-
ence of lymph node metastasis (33). Although the precise biological
role of S100A11 in cancer remains unclear, the autochthonous KP
model of lung adenocarcinoma represents an ideal setting for
studying whether S100A11 has a functional role in the pathogenesis
of lung cancer.
Role of Tnc in Tumorigenesis. Along with the S100 proteins, we also
identified up-regulation of Tnc in high-grade KP tumors and me-
tastases. In the developing embryo, Tnc expression is restricted to
areas of active migration and epithelial-to-mesenchymal transition,
whereas after birth its levels are down-regulated in all tissues (34).
However, in adults, Tnc expression is increased at sites of in-
flammation and wound healing, as well as in cancers. Numerous
clinical reports have shown up-regulation of Tnc in patients with
diverse cancer types. Consistent with our results, high Tnc ex-
pression also has been observed in patients with lung cancer (35).
Whereas the roles of Tnc in tumor cell lines have been studied
extensively, the results have led to sometimes conflicting findings,
and relatively few studies have used mouse cancer models. To better
understand the contribution of Tnc to breast cancer, Talts et al. (36)
crossed Tnc-knockout mice to the MMTV-PyMT model, and
reported that a lack of Tnc had no effect on primary tumor growth
or metastatic dissemination to the lungs. Similarly, knockdown of
Tnc in a human breast cancer cell line implanted into the mammary
fat pad of immunodeficient mice had no effect on primary tumor
growth, but did reduce metastasis to the lungs (37). In this context,
tumor-derived Tnc has been found to promote the outgrowth of
pulmonary lesions by enhancing Wnt and Notch signaling, thereby
promoting the viability of cancer cells. Similar results were reported
in a mouse model of pancreatic neuroendocrine cancer, in which
Tnc was found to promote tumorigenesis and lung metastasis (38).
These differing effects of Tnc on cancer may reflect the tumor type-
specific or oncogene-specific roles of Tnc in cancer progression.
Here, using the CRISPR/Cas9 SAM system to overexpress Tnc
from its endogenous promoter in tumor cells, we have shown that
Tnc can promote the spread of lung adenocarcinoma cells without
affecting primary tumor growth. Previous studies have identified
cancer-associated fibroblasts as a major source of Tnc in tumors
(39), but whether stroma-derived Tnc has a role in tumor pro-
gression in this model is unclear. Although the precise mechanism
of action remains to be elucidated, we have shown that Tnc is a
target of the transcription factor Nkx2-1, which has been shown to
suppress lung cancer progression and metastasis through the sup-
pression of embryonic genes (19). Thus, Nkx2-1 appears to exert its
effects through various factors, including the ECM protein Tnc.
Whereas the effect of Nkx2-1 on Tnc is likely direct, this possibility
requires further investigation using promoter luciferase assays.
Whether the same relationship is true in humans remains to
be proven, although it is likely, given that the human and
mouse Nkx2-1 proteins share 98% identity, and that two of
the Nkx2-1 binding sites that we identified in the murine Tnc
promoter are conserved in the human Tnc promoter (peak 2, 75%
identify; peak 3, 80% identify). Moreover, Tnc might not be the
sole ECM factor regulated by Nkx2-1; analysis of existing Nkx2-1
ChIP-Seq data (20) identified potential Nkx2-1 binding sites
within 4 kb of the transcriptional start sites of 14 of the 36 matri-
somal proteins detected in differential abundance in KP lung tu-
mors (Agrn, Col12a1, Col16a1, Ctsd, Fbln5, Hspg2, Lgals3, Ltbp2,
Nid1, Nid2, Npnt, S100a11, Sftpb, Sftpd, Tnc). Further work is
needed to confirm whether these genes are also transcriptionally
regulated by Nkx2-1, and whether they affect metastasis.
Because Tnc expression is absent in normal adult tissues but
highly up-regulated in many solid cancers, it represents an ideal
diagnostic marker and therapeutic target in cancers (40). In sev-
eral compounds currently in clinical trials, antibodies against Tnc
have been conjugated to either radioactive compounds that can
inhibit tumor growth or IL-2, aimed at improving the efficacy of
chemotherapy. Another area showing promise is the development
of therapeutic or preventive cancer vaccines in which Tnc could be
targeted alone or in combination with other factors (41).
Materials and Methods
Mouse Strains and Treatments. The Massachusetts Institute of Technology’s In-
stitutional Animal Care and Use Committee approved all animal studies and
procedures. C57BL/6J mice were purchased from Jackson Laboratories. To in-
duce pulmonary fibrosis, 6- to 8-wk-old C57BL/6 mice were treated with a single
dose of 0.035 U of bleomycin sulfate (Selleck Chemicals; S1214) or PBS intra-
tracheally. The mice were killed 2 wk later, and the lungs were harvested. For
the lung tumor model, we used KP mice, in which tumor development was
initiated by intratracheal infection with Cre-expressing adenoviruses (University
of Iowa Gene Transfer Core). Primary tumors and associated metastases to the
mediastinal lymph nodes were harvested from the samemouse. One-half of the
lung tissues and one-half of the tumors were flash-frozen and stored at −80 °C
before MS analysis; the other halves were fixed in 4% zinc formalin overnight
and then embedded in paraffin. Primary tumors were graded by a pathologist
(R. Bronson) following established criteria (42), and only advanced (grades
3 and 4) tumors were used for the analysis. For the transplantation studies, 105
KP tumor cells (1233 line) (43) were injected via the lateral tail vein into mice or
5 × 105 KP tumor cells were injected s.c.
Tissue Decellularization and ECM Protein Enrichment. Decellularization of samples
ranging from 50 to 100 mg was performed using the CNMCS compartmental
protein extraction kit (EMD Millipore), as described previously (9, 13). In brief,
frozen samples were homogenized with a Bullet Blender (Next Advance)
according to the manufacturer’s instructions and then incubated in a series of
buffers to remove, sequentially, cytosolic proteins, nuclear proteins, membrane
proteins, and cytoskeletal proteins. The remaining insoluble pellet is enriched for
ECM proteins. Three independent samples of each tissue type—normal lung,
fibrotic lung, advanced stage lung adenocarcinoma, and derived lymph-node
metastasis—were processed. The effectiveness of the decellularization and
concomitant ECM protein enrichment was monitored by immunoblotting using
the following antibodies: GAPDH (EMD Millipore; MAB374), pan-histones (Up-
state Biotechnology; 05-858), collagen I (EMD Millipore; AB765P), collagen IV
(Abcam; ab6586), actin (clone 14-1, generated by the R.O.H. laboratory), and Fn
(rabbit 297-1, generated by the R.O.H. laboratory).
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MS Analysis. The procedure for digesting proteins into peptides and proteomic
analysis are descriced in detail in SI Materials and Methods. The raw MS data
have been deposited at the ProteomeXchange Consortium via the PRIDE
partner repository (dataset identifier PXD003517).
IHC. Mice were killed by CO2 asphyxiation, and lungs were inflated with 10%
zinc/formalin (Polysciences), fixed overnight in zinc/formalin at room temper-
ature, and then transferred to 70% ethanol and embedded in paraffin. Mas-
son’s trichrome staining was performed following standard procedures. IHC
was performed on 5-μm-thick sections using the ABC Vectastain Kit (Vector
Laboratories) with antibodies to Tnc (1:400; EMD Millipore; AB19011), Nkx2-1
(1:400; Abcam, ab76013), S100A6 (1:500, Abcam ab181975), S100A10 (1:100,
Abcam, ab76472), S100A11 (1:300, Abcam; ab180593), and Fn (1:500; Abcam;
ab2413). The staining was visualized with DAB (Vector Laboratories; SK-4100),
and the slides were counterstained with hematoxylin. Table S1 shows the
number of samples (each sample is an individual mouse) that were stained.
CRISPR Activation. Nonclonal 1233 KP cells (43) stably expressing dCas9-VP64-Blast
(Addgene; 61425) and MS2-P65-HSF1-Hygro (Addgene; 61426) were generated via
sequential lentiviral transduction and selection with blasticidin and hygromicin,
respectively. To overexpress Tnc, we designed and cloned five independent gRNA
sequences targeting the Tnc promoter into a lentiviral vector (Lenti-sgRNA-
MS2-Zeocin; Addgene; 61427) and subsequently transduced and zeocin-selected
the aforementioned cell lines to generate KP cell lines stably expressing all three
components. The target gRNA sequences were designed using the SAM algo-
rithm (sam.genome-engineering.org/database/); PAM sites are in bold: gTNC4
CCGTTAGCTGGCGGCGCGCCTGG, gTNC5 CACAGCCCTCCCAGCGGAACAGG, gTNC6
ATGAAAGACGCACTCACTCCAGG, gTNC7 AACTACTCTGCGGGGGCGGAGGG, and
gTNC8 TTTTTCAGTTGGTGAGTTAAAGG. For analysis of the population doublings,
the cells were grown under standard tissue culture condition, and the number of
cells for each sample was counted every 2 d (in triplicate for each condition).
Clinical Data Analyses. RNA-seq gene expression profiles of primary tumors,
matched normal samples, and relevant clinical data of 488 patients with lung
adenocarcinoma with primary tumor samples were obtained from TCGA
(https://cancergenome.nih.gov/). Details of the bioinformatics analyses are pro-
vided in SI Materials and Methods.
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